Institutional Ownership
Xilio Therapeutics Inc
CUSIP 98422T209COMQ1 2026
13D / 13G Filings
0
Schedule 13D/13G on record
Beneficial Filers
0
Distinct reporting persons
Largest Stake
—
Max % of class reported
Institutional Holders
20
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
Schedule 13D (activist) & 13G (passive) 5%+ ownership filings
No 13D/13G filings on record yet
Schedule 13D/13G beneficial-ownership filings from 2020–present are ingested from SEC EDGAR. Coverage expands as the backfill and daily crawler run.
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 664.0K | $5.58M |
| 2 | Frazier Life Sciences Management, L.P. | 422.5K | $3.55M |
| 3 | Sio Capital Management, LLC | 152.5K | $1.28M |
| 4 | Caligan Partners LP | 112.1K | $943.0K |
| 5 | Merck & Co., Inc. | 106.0K | $891.3K |
| 6 | Stonepine Capital Management, LLC | 64.2K | $539.6K |
| 7 | Morgan Stanley | 57.5K | $483.5K |
| 8 | Renaissance Technologies LLC | 49.6K | $416.9K |
| 9 | Aju Ib Investment Co., Ltd. | 47.7K | $401.1K |
| 10 | Geode Capital Management, LLC | 37.2K | $312.8K |